GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beryl Drugs Ltd (BOM:524606) » Definitions » Capex-to-Operating-Income

Beryl Drugs (BOM:524606) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Beryl Drugs Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Beryl Drugs's Capital Expenditure for the three months ended in Mar. 2024 was ₹0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₹-2.89 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Beryl Drugs Capex-to-Operating-Income Historical Data

The historical data trend for Beryl Drugs's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beryl Drugs Capex-to-Operating-Income Chart

Beryl Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.62 5.47 - 1.10 0.92

Beryl Drugs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Beryl Drugs's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beryl Drugs's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Beryl Drugs's Capex-to-Operating-Income falls into.



Beryl Drugs Capex-to-Operating-Income Calculation

Beryl Drugs's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-13.516) / 14.732
=0.92

Beryl Drugs's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -2.893
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beryl Drugs  (BOM:524606) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Beryl Drugs Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Beryl Drugs's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Beryl Drugs (BOM:524606) Business Description

Traded in Other Exchanges
N/A
Address
133, Kanchan Bagh, Ground Floor, Indore, MP, IND, 452001
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.

Beryl Drugs (BOM:524606) Headlines

No Headlines